Helge Bode
Cyril Moccand
Julien Hitce
Julien Hitce, graduated in France from “Chimie Paris” in 2004, with a Master's degree in Chemical Science. He started his journey into Green Chemistry with his PhD (2004-2007), focused on the development of new methodologies and synthetic applications featuring transition-metal catalyzed transformations, especially C–H activation.
After a postdoctoral stay at Stanford (USA), in the B.M. Trost research group, focused on the development of a novel, enantioselective, atom-economical transformation, he joined L’OREAL Research & Innovation in 2009.
He is currently heading a research group dedicated to the development of new cosmetic ingredients, leveraging the potential of Green Chemistry and innovative transformation technologies for skincare and make-up applications.
Research interests:
- Design and synthesis of novel cosmetic ingredients for skin- and hair-care, with a major focus on Color, Optics and UV-protection
- Green Chemistry with a focus on transformations and processes that straightforwardly generate structural complexity/diversity and added-value from renewable building-blocks
- Process development toward industrialization with a focus on limiting the environmental impact of the process.
“Biocatalysis has emerged as a powerful route toward products that combine both performance and sustainability. And new developments will bring new opportunities: a great promise for green synthesis!”
Doru Roiban
Keith Mulholland
Keith was born in and grew up in Liverpool. He obtained his first degree in 1985 at the University of Manchester Institute of Science and Technology, followed by a PhD at the same institution working for Professor Dick Stoodley on C-Nucleoside Synthesis. A Post-Doctoral Fellowship at the University of Texas at Austin working for Professor Philip Magnus on Alkaloid synthesis followed.
He returned to the UK in 1990 to take up a position as a Medicinal Chemist at SmithKline Beecham Harlow working on Serotonin Antagonists for the treatment of Irritable Bowel Syndrome and Depression. In 1996 he moved to the Synthetic Chemistry Department and started work in the area of Process Development.
Following the merger of SmithKline Beecham and Glaxo-Wellcome in 2001, Keith moved to Process R&D AstraZeneca Macclesfield. In his time there he has held various roles. He was the Lead Chemist for the Olaparib project from 2006-2007 and the Catalysis Technology Leader from 2008 to 2011.
Since 2011 he has been the Associate Principal Scientist and Departmental Lead for Biocatalysis within Pharmaceutical Technology and Development.
Andreas Liese
Valentin Nenov
Byron Silva
PROFILE:
- Veterinary with expertise for over 35 years in veterinary products segment working for local and global players. Previous experience in several areas of veterinary industry: vaccine production, QC, R&D, product manager, technical assistance and regulatory affairs.
- Support for technical and regulatory affairs for new and existing business.
- Support for development of new businesses in Brazil for global players.
